Category Archives: – Pharma

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

The Biggest Healthcare Stories of 2016

December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

CDER Director Janet Woodcock on new drug safety strategies

November 16, 2010- by Steven E. Greer, MD We interviewed Dr. Janet Woodcock, long-time Director of CDER, the FDA center responsible

Posted in - Pharma, FDA | Leave a comment

The super shady methods of pricing generic drugs in America: case study- Sildenafil

May 15, 2016- by Steven E. Greer, MD The last I read, Teva and Mylan were not supposed to launch their approved generic of Viagra (sildenafil)

Posted in - Generics, - Opinion, - Pharma, CMS, Congress, FDA | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Insurance companies are not paying for Repatha and Praluent

March 8, 2017- Interviewed by Steven E. Greer, MD We interviewed cardiologist William O’Neill, MD about his personal need for the cholesterol-lowering, large-molecule, antibody drug from Amgen, branded as Repatha. Despite

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | 1 Comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | 1 Comment

The FDA’s new Breakthrough status for new drug applications

May 24, 2013- Interviewed by Steven E. Greer, MD Janet Woodcock, MD,

Posted in - Pharma, FDA | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year. 

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn, MD about his NEJM

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

This could be the best interview ever aired on Fox Business

August 15, 2017- by Steven E. Greer, MD Martin Shkreli was on Fox Business today, and the set seemed familiar. Ironically, I was in this same

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy | Leave a comment

President-elect Trump adopts plan by The Healthcare Channel to bring back drug manufacturing jobs

Update January 11, 2017- By Steven E Greer, MD Last November, I sent my idea, below, directly to the Commissioner of the FDA, Robert Califf. I also sent it

Posted in - Opinion, - Pharma, - Policy, CMS, Congress, FDA | Leave a comment

Review of combination immunotherapies seen at ASCO 2016

June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Robert De Niro gives credibility to vaccine truthers

Update March 27, 2016- Less than 24-hours after our story, this film has been pulled from the lineup. It was our story that got the heads of

Posted in - Pharma, - Reviews, books, devices, CDC, FDA, NIH, Pediatrics, Primary care medicine | Leave a comment

Review of immunotherapy and targeted therapy

June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Preventing HIV infection

July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote

Posted in - Biotech, - NEJM, - Pharma, General surgery, Harvard, Infectious disease, Primary care medicine | Leave a comment